Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | TAK-573 |
Trade Name | |
Synonyms | TAK 573|TEV-48573|TAK573|TEV48573|TEV-48573|Modakafusp Alfa |
Drug Descriptions |
TAK-573 is a fusion of an anti-CD38 antibody and attenuated IFN-alpha, which potentially inhibits tumor growth (Clinical Lymphoma, Myeloma and Leukemia, Volume 19, Issue 10, e116). |
DrugClasses | CD38 Antibody 20 |
CAS Registry Number | 2254522-19-3 |
NCIT ID | C140427 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Bortezomib + Pomalidomide + TAK-573 | Bortezomib Pomalidomide TAK-573 | 0 | 1 |
Bortezomib + TAK-573 | Bortezomib TAK-573 | 0 | 1 |
Carfilzomib + Daratumumab + TAK-573 | Carfilzomib Daratumumab TAK-573 | 0 | 1 |
Carfilzomib + Pomalidomide + TAK-573 | Carfilzomib Pomalidomide TAK-573 | 0 | 1 |
Carfilzomib + TAK-573 | Carfilzomib TAK-573 | 0 | 1 |
Daratumumab + Pomalidomide + TAK-573 | Daratumumab Pomalidomide TAK-573 | 0 | 1 |
Daratumumab + TAK-573 | Daratumumab TAK-573 | 0 | 1 |
Dexamethasone + TAK-573 | Dexamethasone TAK-573 | 0 | 1 |
Lenalidomide + TAK-573 | Lenalidomide TAK-573 | 0 | 1 |
Pomalidomide + TAK-573 | Pomalidomide TAK-573 | 0 | 1 |
TAK-573 | TAK-573 | 0 | 2 |